[Depakine (sodium dipropylacetate) in the treatment of epilepsies resistant to other drugs (EEG clinical study in 35 cases followed up for 3-12 months)].
D000927:Anticonvulsants / Q000627:therapeutic use*; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D009207:Myoclonus / Q000188:drug therapy; D011407:Propane / Q000627:therapeutic use; D014631:Valerates / Q000627:therapeutic use*
D000927:Anticonvulsants; D014631:Valerates; D011407:Propane
Il Depakine (dipropilacetato di sdio) nel trattamento delle epilessie ribelli agli altri farmaci (studio EEG-clinico di 35 casi seguiti per 3-12 mesi.